Navigation Links
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
Date:12/18/2007

ment Board. "We believe we are on track to provide initial results from this clinical trial during the first quarter of 2008."

About Acute Migraine Headaches

According to the National Headache Foundation, approximately 13 million people in the United States have been diagnosed with migraine headaches. Acute migraine headaches occur often, usually one to four times a month. Of the estimated 29.5 million migraine sufferers (including diagnosed and undiagnosed sufferers), there are at least two groups of potential patients for whom we believe AZ-001 and AZ-104 could be effective and safe in comparison to triptans. Many migraine sufferers who do take triptans have an insufficient therapeutic response to these medications. In addition, according to the warning labels on triptans, patients with hypertension or high cholesterol, or who smoke cigarettes, are contraindicated for and should not take these medications due to potential cardiovascular health risks.

About AZ-104 (Staccato loxapine)

AZ-104 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known as antipsychotics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses revealed that peak plasma levels were generally reached within the first few minutes after dosing and the drug exhibited good dose proportionality. Alexza and Symphony Allegro are also developing Staccato loxapine (AZ-004) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. In March 2007, Alexza announced positive initial results from a Phase 2a clinical trial where a 10 mg dose of AZ-004 was statistically significantly effective, compared to placebo, in reducing agitation in schizophrenic patients following self-administration of the drug during an in-clinic study
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation ... Siddhartha Kadia, Ph.D. has joined the company,s Board ... Executive Officer and a director of Evans Analytical ... testing, evaluation and analytical services to companies in ... Prior to joining Evans Analytical Group, Dr. Kadia ...
(Date:12/19/2014)... , Dec. 19, 2014 Breckenridge Pharmaceutical, ... multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... expect to commercialize several new ANDAs.  Under the terms ... the products exclusively to Breckenridge for the U.S. market, ... its label.  Breckenridge and MSN have agreed to develop ...
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... marketplace, innovative consumer research and marketing communication tools ... rich and globally competitive – consequently consumers, desires, ... In this environment, market research groups across ... research and marketing communication tools. However, the adoption ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... begins its year-long, professional development programs this month. ... LEAD, which focuses on nurse educators fast-tracked for ... for the Leadership Development Program for Simulation Educators, ... that specialized area of nursing education. , ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Parker & ... absolute best in Arizona home contracting services reports a ... to its quality services in 2014. As a company ... the early 1970s, Parker and Sons is a business ... The company works side-by-side with other top quality companies ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 Recently, BambooFlooringChina.com, ... durable strand woven bamboo flooring collection , and launched ... 25%. The promotion is valid until Jan. 30, 2015. ... woven bamboo is the hardest bamboo flooring available today; ... resembling that of traditional teak hardwoods. Strand woven bamboo ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... 18 ACM, one of the country,s ... Health Plans, Inc. today announced a new ... and pricing precision to medical,pharmacy infusion services ... over a decade, ACM,s e-Precision Claims(SM) technology ...
... the nation,s,leading supplier of replacement medical repair parts ... NEO award. Team NEO recognizes,the exceptional companies providing ... the engines fueling the Cleveland area economy., ... right about Northern Ohio,business," said President & CEO ...
... researchers have found that the region of the brain ... the thoughts of other people who are similar to ... considering those who are different politically, socially, or religiously. ... of the National Academy of Sciences, the study was ...
... A new UC Irvine study finds that lithium chloride, ... the development of inclusion body myositis, a skeletal muscle ... by scientists Frank LaFerla and Masashi Kitazawa, mice genetically ... six months after receiving daily doses of lithium chloride, ...
... ON. New U of T research holds promise ... also serve as a model for future therapies against ... Igor Stagljar, University of Toronto scientists have identified several ... or ExoS). One of these compounds, exosin, significantly inhibited ...
... Providence Hospital,and St. John Hospital and Medical Center ... major teaching hospitals by one of the country,s ... The recognition from Thomson (formally Solucient), recognizes hospitals,that ... Providence and SJH&MC were two of only ...
Cached Medicine News:Health News:ACM Partners With Tufts Associated Health Plans to Improve the Cost-effective Delivery of Home Infusion Services 2Health News:Introspective experiences inform inferences about similar people -- but not dissimilar 2Health News:Introspective experiences inform inferences about similar people -- but not dissimilar 3Health News:Lithium chloride slows onset of skeletal muscle disorder 2Health News:Lithium chloride slows onset of skeletal muscle disorder 3Health News:Research promising for cystic fibrosis 2Health News:St. John Health Hospitals Honored as Nation's Top 15 Major Teaching Hospitals 2
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
... is your system. CONMED's family of products ... New, state-of-the art generators feature proprietary Energy ... continuous synchronization of current and voltage in ... enables the system to sample current and ...
Medicine Products: